(R)-(+)-HA-966 - CAS 123931-04-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C4H8N2O2
Molecular Weight:
116.12
COA:
Inquire
Targets:
NMDA Receptor
Description:
(R)-(+)-HA-966 is a cell-permeable antagonist/partial agonist at the glycine site of the NMDA receptor.
Brife Description:
NMDA receptor antagonist
Purity:
≥98% by HPLC
Related CAS:
111821-58-0 (S-enantiomer)
Synonyms:
(R)-(+)-3-Amino-1-hydroxypyrrolidin-2-one
MSDS:
Inquire
InChIKey:
HCKUBNLZMKAEIN-GSVOUGTGSA-N
InChI:
InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2/t3-/m1/s1
Canonical SMILES:
C1CN(C(=O)C1N)O
1.The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA receptor antagonist, (+)-HA966 in a rat model of peripheral neuropathy.
Christensen D;Idänpään-Heikkilä JJ;Guilbaud G;Kayser V Br J Pharmacol. 1998 Dec;125(8):1641-50.
1. We evaluated the ability of the functional antagonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor complex, (+)-(1-Hydroxy-3-aminopyrrolodine-2-one) ((+)-HA966), to modulate the antinociceptive action of systemic morphine in a rat model of neuropathic pain produced by chronic constriction injury to the sciatic nerve. Mechanical (vocalization threshold to hindpaw pressure) and thermal (struggle latency to hindpaw immersion into a water bath) stimuli were used. 2. In the mechanical test, morphine (0.05, 0.1 and 0.3 mg kg(-1), i.v.) alone produced dose-dependent effects in both neuropathic and uninjured rats. Likewise, morphine (0.1, 0.3 and 1 mg kg(-1), i.v.) dose-dependently increased struggle latencies of the nerve-injured hindpaw in the hot noxious (46 degrees C) test but was ineffective in the non-noxious warm (44 degrees C) and cold (10 degrees C) test. 3. Pretreatment with (+)-HA966 (2.5 mg kg(-1), s.c.) dose-dependently enhanced the effect of morphine in the mechanical test with the relative potency being nerve-injured hindpaw > contralateral hindpaw > uninjured rat. 4. Likewise, (+)-HA966 dose-dependently enhanced the effect of morphine against a hot (46 degrees C) stimulus and produced, in combination with morphine, a dose-dependent effect against a warm (44 degrees C) stimulus.
2.Antinociceptive effects of NMDA and non-NMDA receptor antagonists in the tail flick test in mice.
Lutfy K;Cai SX;Woodward RM;Weber E Pain. 1997 Mar;70(1):31-40.
Inhibition of spinal glutamate receptors induces antinociceptive effects in numerous animal models of pain. The present study compares the effects of intrathecally administered N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor antagonists on nociceptive responses in the tail flick test. Potency of antagonists at NMDA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors was first measured by electrical assays in Xenopus oocytes expressing rat cerebral cortex poly(A)+ RNA. Subsequently, Swiss Webster mice were injected intrathecally with the antagonists and tested for antinociception. The drugs tested were: NBQX and GYKI-52466, selective AMPA receptor antagonists, ketamine, MK-801, R(+) HA-966 and ACEA-0762, selective NMDA receptor antagonists, and ACEA-1031, ACEA-1328 and ACEA-0593, NMDA receptor antagonists that also show inhibition of non-NMDA receptors. Selective NMDA receptor antagonists induced essentially no antinociceptive effects in the tail flick test. Antinociceptive activity generally correlated with inhibition of AMPA receptors. The exception was the non-competitive AMPA receptor antagonist GYKI-52466, which was unexpectedly weak. This may be due to inadequate dosing, because the compound has limited solubility, or may be due to differences in the non-NMDA receptor subtype-selectivity profile of GYKI-52466 as compared to competitive antagonists such as NBQX.
3.Anticonvulsant activity of antagonists and partial agonists for the NMDA receptor-associated glycine site in the kindling model of epilepsy.
Rundfeldt C;Wlaź P;Löscher W Brain Res. 1994 Aug 8;653(1-2):125-30.
Several previous studies have shown that competitive and uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists are ineffective as anticonvulsants in fully amygdala kindled rats, i.e. a widely-used model of complex-partial seizures (limbic epilepsy). In the present experiments, different categories of ligands for the NMDA receptor-associated glycine modulatory site were evaluated in the kindling model in rats. For this purpose, the 'silent' glycine antagonist 7-chlorokynurenic acid (7-CKA), the low efficacy glycine partial agonist (+)-HA-966 (R(+)-3-amino-1-hydroxypyrrolid- 2-one), and the high efficacy glycine partial agonist D-cycloserine (D-CS) were used. In view of the poor brain penetration of some of these compounds after systemic administration, all drugs were injected bilaterally into the lateral ventricles of fully kindled rat. Anticonvulsant activity was evaluated by determination of the threshold for induction of focal afterdischarges in the amygdala (ADT) and by monitoring seizure parameters (seizure severity, seizure duration, afterdischarge duration) at ADT current. In addition to anticonvulsant activity, the behavioural adverse effects of test drugs were determined.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related NMDA Receptor Products


CAS 64047-73-0 Ro 04-5595

Ro 04-5595
(CAS: 64047-73-0)

Ro 04-5595 hydrochloride is a selective NMDA receptor inhibitor (Ki = 31 nM).

CAS 4682-36-4 Orphenadrine Citrate

Orphenadrine Citrate
(CAS: 4682-36-4)

Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.

CAS 556803-08-8 TCN 213

TCN 213
(CAS: 556803-08-8)

TCN 213 is an NMDA receptor antagonist with selectivity for NR1/NR2A (pIC50 = 5.4) over NR1/NR2B.

Cgp 39653
(CAS: 132472-31-2)

Cgp 39653 is a competitive N-Methyl-D-aspartate (NMDA) receptor antagonist. CGP 39653 can selectively bins to the NMDA receptor as an antagonist with high affin...

CAS 121917-57-5 (-)-MK 801 Maleate

(-)-MK 801 Maleate
(CAS: 121917-57-5)

MK-801 is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.

CAS 202925-60-8 Conantokin-R

Conantokin-R
(CAS: 202925-60-8)

Conantokin-R is a potent and non-competitive NMDA receptor antagonist with IC50 value of 93 nM. It also has NR2 subunit selectivity. It inhibits inward currents...

CAS 139051-78-8 L-689,560

L-689,560
(CAS: 139051-78-8)

L-689,560 is a potent antagonist at the glycine-NMDA receptor site. It is a bioactive chemical.

CAS 25451-15-4 Felbamate

Felbamate
(CAS: 25451-15-4)

Felbamate (Felbatol) is an anticonvulsant drug used in the treatment of epilepsy.

Chemical Structure

CAS 123931-04-4 (R)-(+)-HA-966

Quick Inquiry

Verification code

Featured Items